CLLS
Cellectis·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Buy"
High Gross Profit Margin
EPS Below Expectations
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CLLS
Cellectis S.A.
A biotechnology company that develops immunotherapies and gene-edited allogenic cancer therapies
Biological Technology
01/04/2000
03/25/2015
NASDAQ Stock Exchange
222
12-31
Depository Receipts (Ordinary Shares)
8, rue de la Croix Jarry, 75013 Paris, France
--
Cellectis S.A. was established on January 4, 2000. The company is a clinical-stage biotechnology company that leverages their core proprietary technology to develop gene-edited products with a portfolio of allogeneic chimeric antigen receptor T cells, or candidates in the field of immuno-oncology, and gene-edited hematopoietic stem cells and progenitors, or HSPC, candidates for other therapeutic indications.
Earnings Call
Q2/2025
Estimate EPS-0.15
Actual EPS-0.22
Estimate Revenue11.53M
Actual Revenue16.00M
Cellectis S.A. Q2 2025: Key Contradictions on Arbitration, Alemtuzumab Strategy, and Trial Designs
Aug 05,2025 12:01
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CLLS has released its 2025 Q3 earnings. EPS was reported at 0.01, versus the expected -0.1, beating expectations. The chart below visualizes how CLLS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CLLS has released its 2025 Q3 earnings report, with revenue of 37.16M, reflecting a YoY change of 105.88%, and net profit of 588.00K, showing a YoY change of 102.55%. The Sankey diagram below clearly presents CLLS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
